Precision Immuno-Oncology
Immune checkpoint inhibitors (ICIs) activate the endogenous immune system to target cancer cells, leading to remarkable anti-tumor effects across various cancer types. However, only a minority of patients experience sustained benefits due to resistance mechanisms, and ICIs can cause immune-related adverse events, some which are serious and irreversible. Therefore, identifying patients who are most likely to respond and understanding immunosuppressive mechanisms are crucial for tailoring immunotherapy in a more personalized and effective manner. We focus our translational and preclinical research effort mainly on breast and head and neck cancer.
In our Precision Immuno-Oncology laboratory, we focus on two main aspects:
- We aim is to understand the mechanisms of immunosuppressive communications networks in the tumor microenvironment. Specifically, we are interested in the crosstalk between epithelial-mesenchymal transition (EMT) – which is an important mechanism of cancer cell plasticity – and the myeloid cell compartment.
- Despite the identification of numerous novel biomarkers predicting response to ICI therapy, only a few have clinical relevance. Therefore, we aim to enhance the translatability of identified predictive biomarkers to bridge the gap between research discoveries and tangible patient benefits.
Funding:
- Marlies Schwegler Stiftung
- Nachwuchsförderungs-Grant Inselspital Bern
- Krebsliga Bern
- Gilead Swiss Fellowship
